ECSP10010234A - Piperazinas como agentes antiobesidad - Google Patents

Piperazinas como agentes antiobesidad

Info

Publication number
ECSP10010234A
ECSP10010234A EC2010010234A ECSP10010234A ECSP10010234A EC SP10010234 A ECSP10010234 A EC SP10010234A EC 2010010234 A EC2010010234 A EC 2010010234A EC SP10010234 A ECSP10010234 A EC SP10010234A EC SP10010234 A ECSP10010234 A EC SP10010234A
Authority
EC
Ecuador
Prior art keywords
piperazinas
compounds
antiobesity agents
preparation
dyslipidemias
Prior art date
Application number
EC2010010234A
Other languages
English (en)
Inventor
Michael Higginbottom
Joseph W Boyd
Giles A Brown
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP10010234A publication Critical patent/ECSP10010234A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de fórmula (I), a composiciones farmacéuticas que comprenden estos compuestos, a procesos para su preparación y al uso de estos compuestos como miméticos moduladores del receptor de leptina en la preparación de medicamentos para afecciones asociadas con el aumento de peso, la diabetes tipo 2 y las dislipidemias.
EC2010010234A 2007-12-05 2010-06-04 Piperazinas como agentes antiobesidad ECSP10010234A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0702696 2007-12-05

Publications (1)

Publication Number Publication Date
ECSP10010234A true ECSP10010234A (es) 2010-07-30

Family

ID=40409928

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010234A ECSP10010234A (es) 2007-12-05 2010-06-04 Piperazinas como agentes antiobesidad

Country Status (17)

Country Link
US (3) US7851471B2 (es)
EP (1) EP2229362A1 (es)
JP (1) JP2011506294A (es)
KR (1) KR20100093104A (es)
CN (1) CN102026975A (es)
AU (1) AU2008333173A1 (es)
BR (1) BRPI0819989A2 (es)
CA (1) CA2707555A1 (es)
CO (1) CO6280487A2 (es)
CR (1) CR11479A (es)
DO (1) DOP2010000167A (es)
EA (1) EA201000926A1 (es)
EC (1) ECSP10010234A (es)
IL (1) IL205874A0 (es)
MX (1) MX2010006259A (es)
WO (1) WO2009071658A1 (es)
ZA (1) ZA201003976B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2240447A2 (en) * 2007-12-05 2010-10-20 AstraZeneca AB (Publ) Morpholine derivates as antiobesity agents
WO2009071668A2 (en) * 2007-12-05 2009-06-11 Biovitrum Ab (Publ) Piperazine derivatives and their use as leptin receptor modulators
KR101810975B1 (ko) * 2010-07-08 2017-12-20 에스케이바이오팜 주식회사 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물
JP2014507458A (ja) 2011-03-11 2014-03-27 グラクソ グループ リミテッド Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
US10689360B1 (en) * 2019-01-30 2020-06-23 Insilico Medicine Ip Limited TLR inhibitors
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
CN113149891B (zh) * 2020-01-07 2024-02-02 南京药石科技股份有限公司 一种2-氨基-2-（1-甲基-4-哌啶基）乙醇的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3420193A1 (de) * 1984-05-30 1985-12-05 Boehringer Ingelheim KG, 6507 Ingelheim Neue substituierte pyrrolidinone, verfahren zu ihrer herstellung und arzneimittel
AR008765A1 (es) 1996-06-06 2000-02-23 Smithkline Beecham Plc Un peptido o un derivado, analogo o variante, funcional del mismo, un peptido recombinante o sintetico del mismo, una secuencia nucleotidica y vectorque la contiene, una celula huesped transformada, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un compuesto del
US6057337A (en) * 1998-02-02 2000-05-02 Shiseido Co., Ltd. 1,2-DI-substituted piperidine derivative, hair growth promoter and external composition for skin using the same
JP2001131149A (ja) 1999-11-08 2001-05-15 Sumitomo Pharmaceut Co Ltd 選択的セロトニン再取り込み阻害剤
JP2001261657A (ja) 2000-03-17 2001-09-26 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体
IL155092A0 (en) 2000-09-29 2003-10-31 Glaxo Group Ltd Compounds useful in the treatment of inflammatory diseases
ES2197003B1 (es) * 2002-04-08 2005-03-16 J. URIACH & CIA S.A. Nuevos compuestos antagonistas de integrinas alfa.
EA200600071A1 (ru) 2003-06-20 2006-08-25 Арена Фармасьютикалз, Инк. Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
AU2005311930B9 (en) * 2004-12-03 2009-09-10 Merck Sharp & Dohme Corp. Substituted piperazines as CB1 antagonists
DE102005000666B3 (de) 2005-01-04 2006-10-05 Sanofi-Aventis Deutschland Gmbh Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20090325975A1 (en) 2005-07-15 2009-12-31 Helmut H Buschmann Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
EP1787679A1 (en) 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
WO2007098939A1 (en) 2006-02-28 2007-09-07 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
EP2240447A2 (en) 2007-12-05 2010-10-20 AstraZeneca AB (Publ) Morpholine derivates as antiobesity agents
WO2009071668A2 (en) 2007-12-05 2009-06-11 Biovitrum Ab (Publ) Piperazine derivatives and their use as leptin receptor modulators
WO2009071677A1 (en) 2007-12-05 2009-06-11 Biovitrum Ab (Publ) New compounds iii
JP2011522813A (ja) 2008-06-04 2011-08-04 アストラゼネカ アクチボラグ 低分子レプチン受容体修飾因子
EP2313096A1 (en) 2008-06-04 2011-04-27 AstraZeneca AB (Publ) New compounds v
EP2321276A1 (en) 2008-06-04 2011-05-18 AstraZeneca AB New compounds vii
CN102143747A (zh) 2008-06-04 2011-08-03 阿斯利康(瑞典)有限公司 作为瘦蛋白受体调节剂模拟物的新的吡啶衍生物

Also Published As

Publication number Publication date
DOP2010000167A (es) 2010-06-30
IL205874A0 (en) 2010-11-30
KR20100093104A (ko) 2010-08-24
ZA201003976B (en) 2011-04-28
CO6280487A2 (es) 2011-05-20
US20110059969A1 (en) 2011-03-10
AU2008333173A1 (en) 2009-06-11
US20090181967A1 (en) 2009-07-16
MX2010006259A (es) 2010-08-23
CN102026975A (zh) 2011-04-20
EA201000926A1 (ru) 2011-02-28
BRPI0819989A2 (pt) 2015-05-12
EP2229362A1 (en) 2010-09-22
CA2707555A1 (en) 2009-06-11
WO2009071658A1 (en) 2009-06-11
JP2011506294A (ja) 2011-03-03
US20110046135A1 (en) 2011-02-24
US7851471B2 (en) 2010-12-14
CR11479A (es) 2010-07-19

Similar Documents

Publication Publication Date Title
CO6280487A2 (es) Piperazinas como agentes antiobesidad
CR11801A (es) Derivados de indazol sustituidos con fenilo y benzodioxinilo
CL2008002787A1 (es) Compuestos derivados de piperidina, que presentan actividad moduladora sobre la actividad del receptor gpr 119; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades tales como diabetes tipo 1 y 2, hiperllpidemia, enfermedad coronaria, obesidad y disfuncion erectil.
CR10922A (es) Derivados de indol como antagonistas receptores de s1p1
SV2010003580A (es) Agonistas novedosos de los receptores de glucocorticoides
PA8777101A1 (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal
UY30470A1 (es) Compuestos heteroarilos de cinco heteroatomos sustituidos con fenilo conteniendo nitrogeno, composiciones farmacéuticas y aplicaciones.
CR11455A (es) Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades
ECSP099452A (es) Derivados de éster y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
CR9722A (es) Derivados de benzilpiperazina y su uso medico
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
ECSP099425A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2
CO6470899A2 (es) 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal
NI201100117A (es) Antagonistas de 4 -- azetidinil - 1 - heteroaril - ciclohexanol del ccr2.
ECSP109961A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica
AR053691A1 (es) Agentes endoparasiticidas
CO6341625A2 (es) Derivados de indol como agentes anticáncer
NI201100015A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico.
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
ECSP067028A (es) Profármacos de esteroides con acción androgénica
BRPI0815455C1 (pt) compostos derivados de n-fenilacetamida, composição farmacêutica, composição cosmética, uso cosmético de uma composição, e usos de um composto do mesmo
PA8773601A1 (es) Agonistas cannabinoides de bencimidazol
MX2010006215A (es) Derivados de piperazina y su uso como moduladores del receptor de leptina.